Aluminum hydroxide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1983
- First approval year
- 1983
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Aluminum hydroxide
- Molecular weight
- 78
- Structure (SMILES)
- O[Al](O)O
- alu cap
- Alu-cap
- aludrox
- Aludrox
- aluminum hydroxide component of gaviscon
- Aluminum hydroxide component of gaviscon
- sarpep
- Sarpep
- alcoa c 30bf
- ALCOA C 30BF
- algeldrate anhydrous
- ALGELDRATE ANHYDROUS
- alhydrogel
- Alhydrogel
- ALHYDROGEL
- Alhydrogelâ„¢
- alternagel
- ALTERNAGEL
- alumina hydrate
- ALUMINA HYDRATE
- ALUMINII HYDROXIDUM [WHO-IP LATIN]
- aluminii hydroxidum who ip latin
- aluminium hydroxide
- Aluminium hydroxide
- Aluminium hydroxide [WHO-DD]
- ALUMINIUM HYDROXIDE [WHO-IP]
- aluminium hydroxide dried
- aluminium hydroxide dried gel
- ALUMINIUM HYDROXIDE DRIED GEL
- aluminium hydroxide gel dried
- aluminium hydroxide gel dried who dd
- aluminium hydroxide gel f 500
- ALUMINIUM HYDROXIDE GEL F 500
And 67 more, listed on the interactive page.
- ATC classification codes
- A02AB01
Sources for recorded values
- CAS registry numbers
- 21645-51-2
- ChEMBL ID
- CHEMBL1200706
- InChIKey
- WNROFYMDJYEPJX-UHFFFAOYSA-K
- PubChem compound IDs
- 10176082
- FDA ingredient codes (UNII)
- 5QB0T2IUN0
- 612
- 81948
- Applicant
- CHATTEM SANOFI
- Approval date
- 9 Dec 1983
- Application number
- NDA018685
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
Administration routes
- Oral
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Anthrax
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000778
- Subject identifier
- D000881
- Condition
- Malaria
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Tobacco Use Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003768
- Subject identifier
- D014029
- Condition
- Leishmaniasis, Cutaneous
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005046
- Subject identifier
- D016773
- Condition
- Influenza in Birds
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005222
- Subject identifier
- D005585
- Condition
- Dengue
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005547
- Subject identifier
- D003715
- Condition
- Staphylococcal Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005681
- Subject identifier
- D013203
- Condition
- Hookworm Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007314
- Subject identifier
- D006725
- Condition
- Influenza, Human
- Highest recorded phase
- 1
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 1
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition
- Plague
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009425
- Subject identifier
- D010930
- Condition
- Stomatitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009688
- Subject identifier
- D013280
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition
- Pneumonia, Pneumococcal
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001474
- Subject identifier
- D011018
- Condition
- Schistosomiasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001475
- Subject identifier
- D012552
- Condition
- Shock
- Highest recorded phase
- 1
- Condition identifier
- HP:0031273
- Subject identifier
- D012769
- Condition
- Heartburn
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002268
- Subject identifier
- D006356
- Condition
- Diabetes Mellitus, Type 1
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005147
- Subject identifier
- D003922
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000778
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001068
- Condition identifier
- EFO_0003768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005046
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005547
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005681
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007314
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007328
- Condition identifier
- EFO_0007444
- Condition identifier
- EFO_0009425
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001413
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001475
- Condition identifier
- HP_0031273
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000328
- Condition identifier
- MONDO_0001741
- Condition identifier
- MONDO_0002268
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005645
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007186
And 2 more, listed on the interactive page.
- Event
- acute coronary syndrome
- Reports
- 5
- Reporting signal score
- 10.5293
- Event
- acute cutaneous lupus erythematosus
- Reports
- 4
- Reporting signal score
- 22.6857
- Event
- acute respiratory distress syndrome
- Reports
- 4
- Reporting signal score
- 7.19473
- Event
- angina unstable
- Reports
- 5
- Reporting signal score
- 11.0338
- Event
- blood parathyroid hormone decreased
- Reports
- 4
- Reporting signal score
- 14.9815
- Event
- bordetella test positive
- Reports
- 1
- Reporting signal score
- 6.68833
- Event
- caesarean section
- Reports
- 4
- Reporting signal score
- 6.60982
- Event
- cardiospasm
- Reports
- 2
- Reporting signal score
- 10.7391
- Event
- clostridium difficile colitis
- Reports
- 5
- Reporting signal score
- 10.5723
- Event
- coagulopathy
- Reports
- 4
- Reporting signal score
- 6.81774
- Event
- craniotabes
- Reports
- 2
- Reporting signal score
- 13.7952
- Event
- cutaneous lupus erythematosus
- Reports
- 3
- Reporting signal score
- 8.80095
- Event
- drug interaction
- Reports
- 26
- Reporting signal score
- 28.0938
- Event
- dyspepsia
- Reports
- 7
- Reporting signal score
- 6.98598
- Event
- electrocardiogram qt prolonged
- Reports
- 24
- Reporting signal score
- 55.3824
- Event
- eosinophilic pneumonia
- Reports
- 4
- Reporting signal score
- 12.083
- Event
- faecal vomiting
- Reports
- 2
- Reporting signal score
- 8.87221
- Event
- hepatitis cholestatic
- Reports
- 4
- Reporting signal score
- 8.97354
- Event
- hypercalciuria
- Reports
- 4
- Reporting signal score
- 18.6116
- Event
- hypernatraemia
- Reports
- 4
- Reporting signal score
- 10.5178
- Event
- hypertriglyceridaemia
- Reports
- 7
- Reporting signal score
- 19.2991
- Event
- hypoparathyroidism
- Reports
- 2
- Reporting signal score
- 7.40597
- Event
- hypophosphataemic osteomalacia
- Reports
- 2
- Reporting signal score
- 9.29087
- Event
- hypophosphataemic rickets
- Reports
- 6
- Reporting signal score
- 43.6329
- Event
- immune thrombocytopenia
- Reports
- 5
- Reporting signal score
- 17.9462
And 15 more, listed on the interactive page.
- NCT00000779
- NCT00000809
- NCT00000868
- NCT00001042
- NCT00001044
- NCT00001052
- NCT00001053
- NCT00002402
- NCT03382418
- NCT04177355
- NCT04915768
- NCT06267872
- NCT00001906
- NCT00114010
- NCT00320658
- NCT00341250
- NCT00414336
- NCT00427167
- NCT00889616
- NCT01434381
- NCT01867463
- NCT02334462
- NCT02647489
- NCT02658253
- NCT00120081
And 26 more, listed on the interactive page.
- Dose
- 1-2 tablespoonfuls
- Route
- Oral
- How often
- 4 times a day
- Shake well
- Take after meals
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 4
- Molecular formula
- H3AlO3
- Monoisotopic mass
- 77.9897574
- Natural product
- No
- Adjuvants, Immunologic
- Antacids
Related records
Trials (80)
- A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
- A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
- A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
- A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
- A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
- A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
- A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines
- A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine
- A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria
- A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
- A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
- AMA1-C1/Alhydrogel + CpG 7909 for Malaria
- Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
- Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
- Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
Approved for (1)
- Dyspepsia
In development for (18)
- Anthrax infection Phase 2
- Avian influenza Phase 2
- Cutaneous leishmaniasis Phase 1
- Dengue disease Phase 1
- HIV infectious disease Phase 1
- Hookworm infectious disease Phase 2
- Influenza Phase 1
- Malaria Phase 1
- Nicotine dependence Phase 2
- Plague Phase 1
- Plasmodium falciparum malaria Phase 1
- Respiratory syncytial virus infectious disease Phase 1
- Schistosomiasis Phase 1
- Severe acute respiratory syndrome Phase 1
- Staphylococcus aureus infection Phase 1
- Stomatitis Phase 2
- Streptococcal pneumonia Phase 2
- Type 1 diabetes mellitus Phase 2